Rapport Therapeutics, Inc. (RAPP)
| Market Cap | 1.20B -10.0% |
| Revenue (ttm) | 20.00M |
| Net Income | -137.16M |
| EPS | -3.05 |
| Shares Out | 47.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 926,555 |
| Open | 23.94 |
| Previous Close | 24.21 |
| Day's Range | 23.86 - 25.43 |
| 52-Week Range | 22.06 - 52.93 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 68.29 (+172.62%) |
| Est. Earnings | Nov 13, 2026 |
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorde... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for RAPP stock is "Strong Buy." The 12-month stock price target is $68.29, which is an increase of 172.62% from the latest price.
News
Citizens biotech analysts hold an analyst/industry conference call
Biotech Analysts discuss novel therapies and novel mechanisms for Bipolar Mania (RAPP) on an Analyst/Industry conference call to be held on November 4.
Rapport Therapeutics 8.333M share Spot Secondary priced at $21.00
The deal range was $21.00-$22.00. Morgan Stanley, Leerink and Evercore ISI acted as joint book running managers for the offering.
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
BOSTON and SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Rapport announces $200M common stock, $150M convertible senior notes offerings
Rapport Therapeutics (RAPP) announced that it has commenced separate underwritten public offerings of $200M of shares of its common stock and $150M aggregate principal amount of convertible senior not...
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
BOSTON and SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Rapport Therapeutics price target raised to $70 from $65 at Guggenheim
Guggenheim raised the firm’s price target on Rapport Therapeutics (RAPP) to $70 from $65 and keeps a Buy rating on the shares after the company’s Phase 2 trial in bipolar…
Rapport Therapeutics price target raised to $82 from $50 at Jones
Jones raised the firm’s price target on Rapport Therapeutics (RAPP) to $82 from $50 and keeps a Buy rating on the shares. The company’s lead asset RAP-219 met its primary…
Rapport Therapeutics price target lowered to $50 from $51 at Wells Fargo
Wells Fargo lowered the firm’s price target on Rapport Therapeutics (RAPP) to $50 from $51 and keeps an Overweight rating on the shares. The firm sees RAP-219 emerging as an…
Rapport Therapeutics price target raised to $91 from $80 at Citizens
Citizens analyst Jason Butler raised the firm’s price target on Rapport Therapeutics (RAPP) to $91 from $80 and keeps an Outperform rating on the shares following the Phase 2 trial…
Rapport Therapeutics price target raised to $86 from $75 at Raymond James
Raymond James raised the firm’s price target on Rapport Therapeutics (RAPP) to $86 from $75 and keeps a Strong Buy rating on the shares. With shares trading roughly flat following…
Rapport Therapeutics price target raised to $66 from $40 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Rapport Therapeutics (RAPP) to $66 from $40 and keeps a Buy rating on the shares. RAP-219 met both primary…
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging
Positive trial data for Rapport's lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak sales opportunity, Jefferies says.
Rapport Therapeutics Transcript: Study result
RAP-219 met both phase II endpoints in bipolar mania, with improving YMRS and CGI results over three weeks and a well-tolerated profile. Phase III is anticipated in H2 2027, with dose and study-design refinements under consideration.
Rapport Therapeutics Press release: Study result
Rapport Therapeutics issued a press release on October 20, 2026, disclosing material business information to investors.
Rapport Therapeutics Slides: Study result
Rapport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2026.
Wells says Rapport’s RAP-219 efficacy looks good, flags some questions on safety
Wells Fargo was impressed by Rapport Therapeutics (RAPP)’ RAP-219 generating a positive efficacy signal in bipolar mania. However, the firm thinks stock upside will be capped given the imbalance in…
Rapport Therapeutics reports ‘positive’ results from Phase 2 trial of RAP-219
Rapport Therapeutics (RAPP) announced positive topline results from its Phase 2 trial of RAP-219 in adults with acute bipolar mania. The trial met its primary endpoint, with RAP-219 achieving a…
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania scor...
Rapport Therapeutics initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Rapport Therapeutics (RAPP) with an Outperform rating and $50 price target
Rapport Therapeutics initiated with a Buy at UBS
UBS initiated coverage of Rapport Therapeutics (RAPP) with a Buy rating and $71 price target The company is developing precision medicine for epilepsies, the analyst tells investors in a research…
Guggenheim starts Rapport Therapeutics at Buy on ‘de-risked’ Phase 2a study
As previously reported, Guggenheim initiated coverage of Rapport Therapeutics (RAPP) with a Buy rating and $65 price target The firm is citing de-risked Phase 3 prospects for the company’s lead…
Rapport Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Rapport Therapeutics (RAPP) with a Buy rating and $65 price target
Rapport drops after CEO presents at TD Cowen Neuropsychiatry Summit
Shares of Rapport Therapeutics (RAPP) were dropping after the company presented at TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit. Of note, CEO Abe Cassey said that he would…
Rapport Therapeutics Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
RAP-219 is advancing in both epilepsy and bipolar mania, leveraging a precision neuroscience approach and targeting significant unmet needs with a differentiated tolerability profile. The bipolar mania program is positioned for pivotal trials, with a strong financial runway and plans for both oral and long-acting injectable formulations.
Rapport Therapeutics Transcript: KOL event
Experts discussed the high unmet need in bipolar mania, emphasizing RAP-219’s novel, targeted mechanism and robust trial design aimed at improving efficacy and tolerability. The phase II trial leverages strict inclusion criteria and advanced analytics, with a positive result potentially expanding the market and offering a differentiated treatment option.